Excimer Light vs. Topical Methotrexate for Scalp Psoriasis Treatment
Study Overview
This study focused on treating scalp psoriasis, which affects 80% of psoriasis patients worldwide. We aimed to compare the effectiveness and safety of two treatments: excimer light and topical methotrexate (MTX) 1% hydrogel.
Methodology
We conducted a randomized study with 30 patients. Each patient’s scalp lesions were divided into two areas:
- Area A: Treated with biweekly excimer light sessions.
- Area B: Treated with daily topical MTX 1% hydrogel for 3 months.
Results
Both treatments showed significant improvement in:
- Psoriatic Scalp Severity Index (PSSI)
- Itching scores
- Dermoscopic red dots and white scales
The average improvement in PSSI was:
- Area A: 75.82%
- Area B: 74.19%
Both treatments were equally effective, with no significant differences in results.
Patient Satisfaction
Patients reported high satisfaction with both treatments, indicating they are both safe and effective options for managing scalp psoriasis.
Practical Solutions & Value
Clinical trials play a vital role in developing effective treatments. Our AI-driven platform, DocSym, integrates clinical standards and research, making it easy for healthcare providers to access vital information.
In today’s healthcare landscape, improving efficiency is essential. Our mobile apps facilitate:
- Scheduling
- Monitoring treatments
- Telemedicine services
By adopting AI technology, clinics can enhance workflows, improve patient outcomes, and reduce reliance on paper processes. Discover more at aidevmd.com.
